Delivery of antiemetics through an inhalation route
First Claim
1. A condensation aerosol for delivery of a drug selected from the group consisting of dolasetron, granisetron and metoclopramide, wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of antiemetics through an inhalation route. Specifically, it relates to aerosols containing antiemetics that are used in inhalation therapy. In a method aspect of the present invention, an antiemetic is delivered to a patient through an inhalation route. The method comprises: a) heating a thin layer of an antiemetic, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% antiemetic degradation products. In a kit aspect of the present invention, a kit for delivering an antiemetic through an inhalation route is provided which comprises: a) a thin layer of an antiemetic drug and b) a device for dispensing said thin layer an antiemetic as a condensation aerosol.
228 Citations
30 Claims
- 1. A condensation aerosol for delivery of a drug selected from the group consisting of dolasetron, granisetron and metoclopramide, wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.
-
4. A method of producing a drug selected from the group consisting of dolasetron, granisetron and metoclopramide in an aerosol form comprising:
-
a. heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns. - View Dependent Claims (5, 6, 16, 17, 18, 19, 20, 21, 22, 23, 24)
-
-
25. A condensation aerosol for delivery of dolasetron, wherein the condensation aerosol is formed by heating a thin layer containing dolasetron, on a solid support, to produce a vapor of dolasetron, and condensing the vapor to form a condensation aerosol characterized by less than 5% dolasetron degradation products by weight, and an MMAD of about 0.2 to 3 microns.
-
26. A condensation aerosol for delivery of granisetron, wherein the condensation aerosol is formed by heating a thin layer containing granisetron, on a solid support, to produce a vapor of granisetron, and condensing the vapor to form a condensation aerosol characterized by less than 5% granisetron degradation products by weight, and an MMAD of about 0.2 to 3 microns.
-
27. A condensation aerosol for delivery of metoclopramide, wherein the condensation aerosol is formed by heating a thin layer containing metoclopramide, on a solid support, to produce a vapor of metoclopramide, and condensing the vapor to form a condensation aerosol characterized by less than 5% metoclopramide degradation products by weight, and an MMAD of about 0.2 to 3 microns.
-
28. A method of producing dolasetron in an aerosol form comprising:
-
a. heating a thin layer containing dolasetron, on a solid support, to produce a vapor of dolasetron, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% dolasetron degradation products by weight, and an MMAD of about 0.2 to 3 microns.
-
-
29. A method of producing granisetron in an aerosol form comprising:
-
a. heating a thin layer containing granisetron, on a solid support, to produce a vapor of granisetron, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% granisetron degradation products by weight, and an MMAD of about 0.2 to 3 microns.
-
-
30. A method of producing metoclopramide in an aerosol form comprising:
-
a. heating a thin layer containing metoclopramide, on a solid support, to produce a vapor of metoclopramide, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% metoclopramide degradation products by weight, and an MMAD of about 0.2 to 3 microns.
-
Specification